How is B7-33 administered?
This describes how B7-33 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily in animal models schedule, generally over pre-clinical, no human protocol. Specific dosing is individual and beyond general information, and human evidence for B7-33 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily in animal models
- Cycle length: Pre-clinical, no human protocol
- Half-life: ~6 min in-vitro native; ~60 min lipidated (no in-vivo PK)
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-15.